• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Tenax Therapeutics Inc.

    11/12/24 9:32:30 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TENX alert in real time by email
    SC 13G 1 p24-3132sc13g.htm TENAX THERAPEUTICS, INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
    (Amendment No. )*
     

    Tenax Therapeutics, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    88032L605

    (CUSIP Number)
     

    September 30, 2024

    (Date of Event Which Requires Filing of This Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ý Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 8 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

      

     

    CUSIP No. 88032L60513GPage 2 of 8 Pages

     

    1

    NAME OF REPORTING PERSON

    Adage Capital Management, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    369,097 shares of Common Stock (including 285,764 shares of Common Stock issuable upon the exercise of warrants)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    369,097 shares of Common Stock (including 285,764 shares of Common Stock issuable upon the exercise of warrants)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    369,097 shares of Common Stock (including 285,764 shares of Common Stock issuable upon the exercise of warrants)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.99%

    12

    TYPE OF REPORTING PERSON

    PN; IA

             

     

     

     

    CUSIP No. 88032L60513GPage 3 of 8 Pages

      

    1

    NAME OF REPORTING PERSON

    Robert Atchinson

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    369,097 shares of Common Stock (including 285,764 shares of Common Stock issuable upon the exercise of warrants)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    369,097 shares of Common Stock (including 285,764 shares of Common Stock issuable upon the exercise of warrants)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    369,097 shares of Common Stock (including 285,764 shares of Common Stock issuable upon the exercise of warrants)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.99%

    12

    TYPE OF REPORTING PERSON

    IN; HC

             

     

     

    CUSIP No. 88032L60513GPage 4 of 8 Pages

      

    1

    NAME OF REPORTING PERSON

    Phillip Gross

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH:
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    369,097 shares of Common Stock (including 285,764 shares of Common Stock issuable upon the exercise of warrants)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    369,097 shares of Common Stock (including 285,764 shares of Common Stock issuable upon the exercise of warrants)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    369,097 shares of Common Stock (including 285,764 shares of Common Stock issuable upon the exercise of warrants)

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.99%

    12

    TYPE OF REPORTING PERSON

    IN; HC

             

     

     

     

     

    CUSIP No. 88032L60513GPage 5 of 8 Pages

      

    Item 1(a). NAME OF ISSUER
       
      The name of the issuer is Tenax Therapeutics, Inc. (the “Company”).

     

    Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES
       
      The Company’s principal executive offices are located at 101 Glen Lennox Drive, Suite 300, Chapel Hill, NC 27517.

     

    Item 2(a). NAME OF PERSON FILING
       
      This statement is filed by:

     

      (i) Adage Capital Management, L.P., a Delaware limited partnership (“ACM”), as the investment manager of Adage Capital Partners, L.P., a Delaware limited partnership (“ACP”), with respect to the shares of Common Stock and the shares of Common Stock issuable upon exercise of warrants directly held by ACP;
       
      (ii) Robert Atchinson (“Mr. Atchinson”), as (1) managing member of Adage Capital Advisors, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ACA”), managing member of Adage Capital Partners GP, L.L.C., a limited liability company organized under the laws of the State of Delaware (“ACPGP”), general partner of ACP and (2) managing member of Adage Capital Partners LLC, a Delaware limited liability company (“ACPLLC”), general partner of ACM, with respect to the shares of Common Stock and the shares of Common Stock issuable upon exercise of warrants  directly held by ACP; and
       
      (iii) Phillip Gross (“Mr. Gross”), as (1) managing member of ACA, managing member of ACPGP and (2) managing member of ACPLLC, general partner of ACM, with respect to the shares of Common Stock and the shares of Common Stock issuable upon exercise of warrants  directly held by ACP.

     

      The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons.”  Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.
       
      The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
       
      The address of the business office of each of the Reporting Persons is 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116.

     

    Item 2(c). CITIZENSHIP
       
      ACM is a limited partnership organized under the laws of the State of Delaware.  Messrs. Gross and Atchinson are citizens of the United States.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES
       
      Common Stock, par value $0.0001 per share (the “Common Stock”).

     

    CUSIP No. 88032L60513GPage 6 of 8 Pages

      

    Item 2(e). CUSIP NUMBER
       
      88032L605

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO Rules 13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act;
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act;
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act;
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940;
      (e) þ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

     

      (g) þ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
      (h) ¨

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

     

      (i) ¨

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

     

      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

      If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please
      specify the type of institution: Not applicable.

     

    Item 4. OWNERSHIP
       
      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.
       
      The percentage set forth in this Schedule 13G is calculated based upon 3,408,906 shares of Common Stock outstanding as of August 10, 2024, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the Securities and Exchange Commission on August 13, 2024, and assumes the exercise of the reported warrants held by ACP.

     

    CUSIP No. 88032L60513GPage 7 of 8 Pages

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
       
      Not applicable.

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
       
      See Item 2(a).

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP
       
      Not applicable.

     

    Item 10. CERTIFICATION
       
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    CUSIP No. 88032L60513GPage 8 of 8 Pages

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    DATE: November 12, 2024

     

    ADAGE CAPITAL MANAGEMENT, L.P.  
    By: Adage Capital Partners LLC,  
    its general partner  
       
    /s/ Robert Atchinson  
    Name:  Robert Atchinson  
    Title: Managing Member  
       
    /s/ Robert Atchinson  
    ROBERT ATCHINSON, individually  
       
    /s/ Phillip Gross  
    PHILLIP GROSS, individually  

     

    Get the next $TENX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TENX

    DatePrice TargetRatingAnalyst
    3/17/2026$35.00Overweight
    Cantor Fitzgerald
    9/8/2025$20.00Overweight
    Piper Sandler
    10/24/2024$16.00Outperform
    Leerink Partners
    10/14/2024$16.00Buy
    Guggenheim
    9/30/2024Outperform
    William Blair
    More analyst ratings

    $TENX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Tenax Therapeutics with a new price target

    Cantor Fitzgerald initiated coverage of Tenax Therapeutics with a rating of Overweight and set a new price target of $35.00

    3/17/26 8:15:05 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Tenax Therapeutics with a new price target

    Piper Sandler initiated coverage of Tenax Therapeutics with a rating of Overweight and set a new price target of $20.00

    9/8/25 8:59:21 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Tenax Therapeutics with a new price target

    Leerink Partners initiated coverage of Tenax Therapeutics with a rating of Outperform and set a new price target of $16.00

    10/24/24 6:39:21 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TENX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Staab Thomas R Ii was granted 10,000 shares (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    5/13/26 5:08:07 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Staab Thomas R Ii claimed no ownership of stock in the company (SEC Form 3)

    3 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    5/13/26 4:56:40 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Interim CFO Mcgauley Thomas

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    2/3/26 5:57:56 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TENX
    SEC Filings

    View All

    SEC Form 8-K filed by Tenax Therapeutics Inc.

    8-K - TENAX THERAPEUTICS, INC. (0000034956) (Filer)

    6/4/26 4:10:06 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Tenax Therapeutics Inc.

    SCHEDULE 13G/A - TENAX THERAPEUTICS, INC. (0000034956) (Subject)

    5/15/26 6:55:54 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Tenax Therapeutics Inc.

    SCHEDULE 13G/A - TENAX THERAPEUTICS, INC. (0000034956) (Subject)

    5/15/26 10:35:56 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TENX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Rich Stuart bought $50,792 worth of shares (5,000 units at $10.16), increasing direct ownership by 90% to 5,266 units (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    12/10/25 6:48:57 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Rich Stuart bought $45,622 worth of shares (5,000 units at $9.12), increasing direct ownership by 940% to 2,766 units (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    12/5/25 5:46:32 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO Giordano Christopher Thomas bought $20,000 worth of shares (2,605 units at $7.68) (SEC Form 4)

    4 - TENAX THERAPEUTICS, INC. (0000034956) (Issuer)

    11/20/25 6:38:51 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TENX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

    On track to report topline data from Phase 3 LEVEL study of TNX-103 in third quarter of 2026 Global Phase 3 LEVEL-2 clinical trial ongoing, enrollment completion anticipated by end of 2027 Strengthened leadership team with appointments of Thomas Staab as Chief Financial Officer and Timothy Healey, MBA, as Chief Commercial Officer CHAPEL HILL, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, reported today financial results for the quarter ended March 31, 2026 and provided an update on its

    5/12/26 7:00:00 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CHAPEL HILL, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced it has awarded or will award inducement option awards between April 28, 2026 and June 1, 2026 as material inducements to the employment of four non-executive individuals newly hired by the Company in various clinical operations, medical, product development, and commercial roles. The employees received or will receive, in the aggregate, non-qualified stock options to purchase 657,500 shares of the Company's common

    5/8/26 4:05:00 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer

    CHAPEL HILL, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today the appointment of Timothy Healey, MBA, as Chief Commercial Officer (CCO), effective immediately. Mr. Healey is a proven commercial leader who has led several successful drug launches and joins Tenax to oversee its global commercial strategy. "Tim is a transformational commercial leader with a proven ability to translate complex science into successful product launches," said Chris Giordano, President and Chief Exe

    5/4/26 7:00:00 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TENX
    Leadership Updates

    Live Leadership Updates

    View All

    Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

    On track to report topline data from Phase 3 LEVEL study of TNX-103 in third quarter of 2026 Global Phase 3 LEVEL-2 clinical trial ongoing, enrollment completion anticipated by end of 2027 Strengthened leadership team with appointments of Thomas Staab as Chief Financial Officer and Timothy Healey, MBA, as Chief Commercial Officer CHAPEL HILL, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, reported today financial results for the quarter ended March 31, 2026 and provided an update on its

    5/12/26 7:00:00 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer

    CHAPEL HILL, N.C., May 04, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today the appointment of Timothy Healey, MBA, as Chief Commercial Officer (CCO), effective immediately. Mr. Healey is a proven commercial leader who has led several successful drug launches and joins Tenax to oversee its global commercial strategy. "Tim is a transformational commercial leader with a proven ability to translate complex science into successful product launches," said Chris Giordano, President and Chief Exe

    5/4/26 7:00:00 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer

    Mr. Staab has over 25 years of financial and executive experience across the healthcare industry CHAPEL HILL, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, announced today the appointment of Thomas R. Staab, II as Chief Financial Officer (CFO), effective May 11, 2026. Mr. Staab brings over 25 years of leadership experience across management and corporate finance roles in the healthcare industry. He will replace Thomas McGauley, who has served as interim CFO since December 2024. "Tom br

    4/22/26 7:00:00 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TENX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Tenax Therapeutics Inc.

    SC 13G - TENAX THERAPEUTICS, INC. (0000034956) (Subject)

    11/14/24 7:14:21 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tenax Therapeutics Inc.

    SC 13G/A - TENAX THERAPEUTICS, INC. (0000034956) (Subject)

    11/14/24 12:21:05 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tenax Therapeutics Inc.

    SC 13G/A - TENAX THERAPEUTICS, INC. (0000034956) (Subject)

    11/13/24 5:35:29 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TENX
    Financials

    Live finance-specific insights

    View All

    Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected in Second Half of 2026 On Track to Initiate Second Phase 3 Study, LEVEL-2, in 2025 Tenax to Host Virtual KOL Call Tomorrow, Thursday, November 13, 2025 at 4:30 p.m. ET CHAPEL HILL, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (NASDAQ:TENX) ("Tenax" or "Tenax Therapeutics" or the "Company"), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today reported financial results for the quarter ended September 30, 2025 and provided an update on its recent corporate progress. "We c

    11/12/25 4:05:00 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tenax Therapeutics Reports First Quarter 2021 Results and Provides Business Update

    Tenax Therapeutics, Inc. (NASDAQ:TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today reported financial results for the first quarter of 2021 and provided a business update. "Having completed the merger with PHPrecisionMed Inc., we now have product development programs in group one and group two pulmonary hypertension patients," stated Anthony DiTonno, Chief Executive Officer of Tenax, "which represent more than 70% of the overall market. "We have begun the open label transition study using the oral formulation of Levosimendan, which was recently acq

    5/17/21 5:15:00 PM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tenax Therapeutics, Inc. Announces Transformative Acquisition of PH Precision Med

    MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products for the critical care market, today announced the acquisition of PH Precision Med (PHPM), a privately-held clinical stage biotech company focused on developing imatinib for the treatment of pulmonary arterial hypertension (PAH). The FDA has granted Orphan Drug Designation for imatinib for the treatment of PAH, an indication with a high unmet medical need. The acquisition expands Tenax’s pulmonary hypertension pipeline with the addition of imatinib, a Phase 3 ready candidate. Imatinib is a tyrosine kinase i

    1/19/21 7:45:00 AM ET
    $TENX
    Biotechnology: Pharmaceutical Preparations
    Health Care